Clinical Trials Arena August 13, 2024
The financing round takes the total funds that the company has raised to date to $202m.
US-based biotechnology company Halda Therapeutics has secured $126m in a Series B extension financing round to progress some of its cancer therapies into clinical trials.
The company’s Regulated Induced Proximity Targeting Chimeras (RIPTAC) therapies are designed to target major solid tumours such as prostate and breast cancer.
The financing round increased Halda Therapeutics’ total funds raised to $202m, which the company will use to begin trials of two RIPTAC candidates.
It included contributions from new investors such as Frazier Life Sciences, Deep Track Capital and RA Capital Management, as well as existing investors Canaan Partners, Elm Street Ventures, Access Biotechnology and Connecticut Innovations.
Halda’s...
Today's Sponsors
Today's Sponsor